We are live on ! Find out more
IMUC.WS

ImmunoCellular Therapeutics Ltd.
IMUC.WS

Delisted

IMUC.WS was delisted on the 16th of October, 2018.

Back to rankings

1 hedge funds and large institutions have $29K invested in ImmunoCellular Therapeutics Ltd. in 2018 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% less capital invested

Capital invested by funds: $55K → $29K (-$26K)

75% less funds holding

Funds holding: 4 → 1 (-3)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
1
Holders Change
-3
Holders Change %
-75%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
3
Calls
$7K
Puts
–
Net Calls
+$7K
Net Calls Change
+$7K

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$11.9K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
AFM
1
Anson Funds Management
Texas
$29K – – –
SM
2
Sabby Management
Florida
– -$11.9K -392,702 Closed
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
– -$2K -43,100 Closed

IMUC.WS Hedge Fund Activity: Q1 2018 in Review

1 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics Ltd. (IMUC.WS) for Q1 2018, worth a combined $29K — down 47% from $55K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of IMUC.WS and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Sabby Management, exiting entirely with an estimated $11.9K sold.

  • 1 institutional investor held ImmunoCellular Therapeutics Ltd. (IMUC.WS) as of Q1 2018, down from 4 in Q4 2017.
  • Funds reported $29K of ImmunoCellular Therapeutics Ltd. stock for Q1 2018, down 47% quarter-over-quarter.
  • 0 funds opened new ImmunoCellular Therapeutics Ltd. positions in Q1 2018 and 3 closed out, a net change of -3 holders.
  • The largest ImmunoCellular Therapeutics Ltd. seller in Q1 2018 was Sabby Management, an estimated $11.9K sold.

Based on aggregated 13F filings for Q1 2018.